SECTIONS OF FEDERAL FOOD, DRUG, AND COSMETIC ACT INVOLVED IN VIOLATIONS REPORTED IN D. D. N. J. NOS. 4761–4780

Adulteration, Section 501 (a) (1), the article consisted in part of a filthy substance; 501 (c), the article was not subject to the provisions of Section 501 (b), and its strength differed from that which it purported or was represented to possess; Section 501 (d) (2), the article was a drug, and a substance had been substituted wholly or in part therefor.

Misbranding, Section 502 (a), the labeling of the article was false and misleading; Section 502 (b), the article was in package form, and it failed to bear a label containing (1) the name and place of business of the manufacturer, packer, or distributor, and (2), an accurate statement of the quantity of contents; Section 502 (d), the article contained a chemical derivative of barbituric acid, and its label failed to bear the quantity or proportion of such derivative and in juxtaposition therewith the statement "Warning—May be habit forming"; Section 502 (e) (1), the article was not designated solely by a name recognized in an official compendium, and its label failed to bear the common or usual name of the drug; Section 502 (e) (2), the article was not designated solely by a name recognized in an official compendium and was fabricated from two or more ingredients, and its label failed to bear the common or usual name of each active ingredient; Section 502 (f) (1), the labeling of the article failed to bear adequate directions for use; Section 502 (i) (3), the article was offered for sale under the name of another drug; Section 502 (l), the article purported to be and was represented as a drug composed wholly or partly of a kind of chlortetracycline or a derivative thereof, and it was not from a batch with respect to which a certificate or release had been issued pursuant to Section 507; Section 503 (b) (4), the article was subject to Section 503 (b) (1), and its label failed to bear the statement "Caution: Federal law prohibits dispensing without prescription."

DRUGS REQUIRING CERTIFICATE OR RELEASE, FOR WHICH NONE HAD BEEN ISSUED

4761. Steclin capsules, Altepose tablets, and Feosol tablets. (F. D. C. No. 37952. S. Nos. 21–814/5 M, 21–817 M.)

QUANTITY: 1 btl. containing 430 *Steclin capsules*, 1 btl. containing 300 *Altepose tablets*, and 1 btl. containing 1,900 *Feosol tablets* at Philadelphia, Pa.

SHIPPED: 11–12–54 and 2–5–55, from Long Island, N. Y., by Carl H. Kaplan, t/a Economy Buying Service, Inc.

LABEL IN PART: (Btl.) "500 Steclin," "1000 Altepose," and "Feosol Tab."

LIBELED: 4–28–55, E. Dist. Pa.

CHARGE: 502 (b) (1)—the three articles when shipped failed to bear labels containing the name and place of business of the manufacturer, packer, or distributor; 502 (b) (2)—the *Steclin capsules* and *Feosol tablets* failed to bear labels containing an accurate statement of the quantity of contents; 502 (d)—the *Altepose tablets* contained a quantity of vinbarbital, a habit forming derivative of barbituric acid, and its label failed to state the quantity or proportion of such derivative and in juxtaposition therewith the statement: "Warning: May Be Habit Forming"; 502 (e) (1)—the label of the *Steclin capsules* failed to bear the common or usual name of the drug; 502 (e) (2)—the label of the *Altepose tablets* and *Feosol tablets* failed to bear the common or usual name of each active ingredient; 502 (f) (1)—the labeling of the three

articles failed to bear adequate directions for use; 502 (l)—the *Steclin capsules* purported to be and were represented as a drug composed wholly or partly of a derivative of chlortetracycline, and they were not from a batch with respect to which a certificate or release had been issued pursuant to law; and 503 (b) (4)—the *Steclin capsules* and the *Altepose tablets* were drugs which were subject to the provisions of 503 (b) (1), and their labels failed to bear the statement "Caution: Federal law prohibits dispensing without prescription."

DISPOSITION: 7–27–55. Default—destruction.

DRUGS IN VIOLATION OF PRESCRIPTION LABELING REQUIREMENTS*

4762. Gray, white, and pink tablets containing, among other ingredients, amphetamine phosphate racemic, thyroid, atropine sulfate, and phenobarbital. (F. D. C. No. 35590. S. Nos. 64–264/6 L.)

INFORMATION FILED: 2–3–55, Dist. Alaska, against Prentiss George Jones, a pharmacist, Anchorage, Alaska.

CHARGE: On 9–2–53, a quantity of *gray, white, and pink tablets containing, among other ingredients, amphetamine phosphate racemic, thyroid, atropine sulfate, and phenobarbital*, was caused, after shipment in interstate commerce, to be held for sale in a small bottle which failed to bear a label containing the statement "Caution: Federal law prohibits dispensing without prescription," contrary to the provisions of 503 (b) (4).

PLEA: Guilty.

DISPOSITION: 6–24–55. $50 fine.

4763. Ascoramide tablets and Denta-Serts. (F. D. C. No. 38181. S. Nos. 18–891 M, 18–899 M.)

QUANTITY: 33 btls. containing 100 *Ascoramide tablets* each and 1 btl. containing 100 *Denta-Serts* at Chattanooga, Tenn.

SHIPPED: On an unknown date, from Columbus, Ohio, by Warren-Teed Products Co.

LABEL IN PART: (Btl.) "100 C. T. Creased * * * Warren-Teed Tablets Ascoramide Each tablet contains: Nicotinamide 50 mg., Ascorbic Acid 50 mg., Lactose Q. S." and "100 C. T. * * * Warren-Teed Denta-Serts (Sulfanilamide with Chlorophyll Wedges) Each compressed wedge contains sulfanilamide 0.12 Gm. (2 grs.) with chlorophyll For local chemotherapeutic action as an aid in preventing infection and dry socket and to aid in healing."

LIBELED: 6–15–55, E. Dist. Tenn.

CHARGE: *Ascoramide tablets.* 502 (a)—the statement on the label of the article when shipped "for the treatment of deficiency conditions associated with Vincent's infection, gingivitis and bleeding gums" was false and misleading since the article was not an effective treatment for such conditions.

Denta-Serts. 503 (b) (4)—the article was a drug subject to 503 (b) (1), and, when shipped, its label failed to bear the statement "Caution: Federal law prohibits dispensing without prescription."

DISPOSITION: 7–25–55. Default—destruction.

*See also No. 4761.